Literature DB >> 8485625

The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents.

L J Bristow1, P H Hutson, L Thorn, M D Tricklebank.   

Abstract

1. The effects of the glycine/N-methyl-D-aspartate (NMDA) receptor antagonist, R-(+)-HA-966 on the neurochemical and behavioural responses to phencyclidine (PCP) and dizocilpine (MK-801) have been determined in rodents. 2. In rats, pretreatment with PCP (5 and 10 mg kg-1) or MK-801 (0.25 and 0.5 mg kg-1) dose-dependently stimulated dopamine turnover in nucleus accumbens, amygdala and medial prefrontal cortex, but had no effect in striatum. In contrast, pretreatment with (+)-HA-966 (10 and 30 mg kg-1) did not affect dopamine turnover in any brain region investigated. 3. Pretreatment with (+)-HA-966 (10 and 30 mg kg-1) significantly antagonized the stimulation of dopamine turnover induced by both PCP (10 mg kg-1) and MK-801 (0.5 mg kg-1) in rat nucleus accumbens, amygdala and medial prefrontal cortex. 4. Intracerebral dialysis studies in conscious rats demonstrated that systemic injection of PCP (10 mg kg-1) markedly stimulated dopamine release from the nucleus accumbens, an effect that was abolished by pretreatment with (+)-HA-966 (30 mg kg-1). 5. Pretreatment with PCP (3-30 mg kg-1) or MK-801 (0.1-1.6 mg kg-1) significantly increased locomotor activity in mice. In contrast, subcutaneous injection of (+)-HA-966 (10-100 mg kg-1) failed to stimulate activity. 6. Pretreatment with (+)-HA-966 (10 and 30 mg kg-1) dose-dependently antagonized both PCP (10 mg kg-1) and MK-801 (0.4 mg kg-1) induced hyperactivity in mice. 7. Blockade of PCP-induced hyperactivity by (+)-HA-966 is unlikely to be explained by the induction or potentiation of sedation/ataxia since PCP-induced rotarod deficits were not significantly different in mice pretreated with (+)-HA-966 (30 mg kg-1) or saline.8. The results demonstrate that (+ )-HA-966 antagonizes both the neurochemical and behavioural effects of PCP and MK-801, possibly through interactions at the glycine/NMDA receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485625      PMCID: PMC1908143          DOI: 10.1111/j.1476-5381.1993.tb13520.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia.

Authors:  P C Contreras
Journal:  Neuropharmacology       Date:  1990-03       Impact factor: 5.250

Review 2.  Noncompetitive excitatory amino acid receptor antagonists.

Authors:  D Lodge; K M Johnson
Journal:  Trends Pharmacol Sci       Date:  1990-02       Impact factor: 14.819

3.  Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo.

Authors:  T Maurice; J Vignon; J M Kamenka; R Chicheportiche
Journal:  J Neurochem       Date:  1991-02       Impact factor: 5.372

4.  Phencyclidine.

Authors:  S H Snyder
Journal:  Nature       Date:  1980-06-05       Impact factor: 49.962

5.  Evidence against an involvement of the haloperidol-sensitive sigma recognition site in the discriminative stimulus properties of (+)-N-allylnormetazocine ((+)-SKF 10,047).

Authors:  L Singh; E H Wong; A C Kesingland; M D Tricklebank
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

6.  Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors.

Authors:  T S Rao; H S Kim; J Lehmann; L L Martin; P L Wood
Journal:  Neuropharmacology       Date:  1990-03       Impact factor: 5.250

7.  Hyperactivity induced by N-methyl-d-aspartate injections into nucleus accumbens: lack of evidence for mediation by dopaminergic neurons.

Authors:  K A O'Neill; R M Carelli; M F Jarvis; J M Liebman
Journal:  Pharmacol Biochem Behav       Date:  1989-12       Impact factor: 3.533

8.  The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites.

Authors:  R B Rothman; A A Reid; J A Monn; A E Jacobson; K C Rice
Journal:  Mol Pharmacol       Date:  1989-12       Impact factor: 4.436

9.  Competitive NMDA receptor antagonists attenuate phencyclidine-induced excitations of A10 dopamine neurons.

Authors:  E D French
Journal:  Eur J Pharmacol       Date:  1992-06-24       Impact factor: 4.432

10.  Phencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.

Authors:  R Quirion; R P Hammer; M Herkenham; C B Pert
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

View more
  23 in total

1.  Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966.

Authors:  J D Jentsch; J D Elsworth; D E Redmond; R H Roth
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

2.  The glycine antagonist (+)-HA-966 injected into the nucleus accumbens stimulates locomotion in mice. (Rapid communication).

Authors:  M Nilsson; M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Felecia M Marottoli; Mercedes Priego; Eden Flores-Barrera; Rohan Pisharody; Steve Zaldua; Kelly D Fan; Giri K Ekkurthi; Scott T Brady; Gerardo A Morfini; Kuei Y Tseng; Leon M Tai
Journal:  Mol Neurobiol       Date:  2019-05-19       Impact factor: 5.590

4.  Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function.

Authors:  Michael A Benneyworth; Alo C Basu; Joseph T Coyle
Journal:  Psychopharmacology (Berl)       Date:  2010-09-24       Impact factor: 4.530

5.  Prefrontal stimulation of GABAA receptors counteracts the corticolimbic hyperactivity produced by NMDA antagonists in the prefrontal cortex of the rat.

Authors:  Alberto Del Arco; Giacomo Ronzoni; Francisco Mora
Journal:  Psychopharmacology (Berl)       Date:  2010-10-28       Impact factor: 4.530

6.  The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.

Authors:  J M Wierońska; M Kusek; K Tokarski; J Wabno; W Froestl; A Pilc
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  Chronic ketamine use increases serum levels of brain-derived neurotrophic factor.

Authors:  Valerio Ricci; Giovanni Martinotti; Francesca Gelfo; Federico Tonioni; Carlo Caltagirone; Pietro Bria; Francesco Angelucci
Journal:  Psychopharmacology (Berl)       Date:  2010-12-14       Impact factor: 4.530

8.  Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.

Authors:  W Löscher; P Wlaź; C Rundfeldt; H Baran; D Hönack
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Authors:  Adem Can; Panos Zanos; Ruin Moaddel; Hye Jin Kang; Katinia S S Dossou; Irving W Wainer; Joseph F Cheer; Douglas O Frost; Xi-Ping Huang; Todd D Gould
Journal:  J Pharmacol Exp Ther       Date:  2016-07-28       Impact factor: 4.030

10.  The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex.

Authors:  M D Tricklebank; L J Bristow; P H Hutson; P D Leeson; M Rowley; K Saywell; L Singh; F D Tattersall; L Thorn; B J Williams
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.